An interventional study of Lenalidomide 10 mg in Oral Ulcer, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment
The study is to evaluate the efficacy and safety of lenalidomide in the treatment of oral ulcers in adult patients with refractory mucosal Behcet's syndrome.
Behçet's Syndrome (BS) is a systemic vasculitis involving blood vessels of all sizes. It is characterised by recurrent oral and genital ulcers, skin lesions, musculoskeletal, ophthalmic, large vessel and intestinal involvements. Mucosal BS is the most common phenotype of BS, commonly treated with thalidomide and colchicine, yet some patients respond poorly or had limited use due to side effects.
Lenalidomide, a second-generation derivative of thalidomide, has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator.
Its neurotoxicity and reproductive toxicity are significantly reduced, and the ability of TNF-alpha inhibition is significantly increased.
Reports on lenalidomide for refractory mucosal BS have been mostly case reports and preliminary studies, clinical trials are lacking.
This is a single-centre, prospective, open-label, single-arm study to evaluate the efficacy and safety of lenalidomide in the treatment of refractory mucosal BS; with the rate of complete remission of oral ulcers in subjects at 12 weeks as the primary endpoint; partial remission of oral and genital ulcers, non-response rate and BS disease activity as secondary endpoints; and adverse events and newly-developed BS-related symptoms as safety endpoints.
This study aims to enroll adult patients with refractory mucosal BS with a stable dosage of low-dose glucocorticoids and/or other conventional immunomodulators. All subjects will be treated with lenalidomide 10mg/day with regular follow-up, those having adverse effects will be evaluated by investigators and adjusted to 5mg/day if necessary, with glucocorticoids and immunosuppressive agents adjusted as needed. Each subject will complete a 12-week treatment period, followed by 4 weeks of observation after cessation of lenalidomide.
41 studies on the registry are indexed under Oral Ulcer; 7 are open to participants now.
This study's planned enrollment of 42 is below the median of 49 across 36 interventional studies indexed under Oral Ulcer.
Browse Oral Ulcer studies →Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria: The presence of any of the following will exclude a subject from the study enrollment.
Exclusion Criteria:
Ten days prior to the day of enrollment for tofacitinib and baricitinib Four weeks prior to the day of enrollment for etanercept Eight weeks prior to the day of enrollment for infliximab Ten weeks prior to the day of enrollment for adalimumab, golimumab, certolizumab, abatacept, and tocilizumab Six months prior to the day of enrollment for secukinumab
All subjects will be treated with lenalidomide 10mg/day.
Drug: Lenalidomide 10 mg
All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
Also known as: Lenalidomide
The complete remission rate of oral ulcers in subjects after 12 weeks of treatment
A complete remission at week 12 was defined as participants who were oral ulcer-free at week 12.
Time frame: 12 weeks
Percentage of participants who had an partial response of oral ulcer at Week 12
A partial response at week 12 was defined as participants with a 50% or more reduction in the number of oral ulcers at week 12
Time frame: 12 weeks
Percentage of participants who had no response of oral ulcer at Week 12
No response at week 12 was defined as all other participants at week 12
Time frame: 12 weeks
Percentage of participants who had a complete response of genital ulcer at Week 12
A complete remission at week 12 was defined as participants who were genital ulcer-free at week 12.
Time frame: 12 weeks
Percentage of participants who had an partial response of genital ulcer at Week 12
A partial response at week 12 was defined as participants with a 50% or more reduction in the number of genital ulcers at week 12
Time frame: 12 weeks
Percentage of participants who had no response of genital ulcer at Week 12
No response at week 12 was defined as all other participants at week 12
Time frame: 12 weeks
Change from baseline on oral ulcer pain as measured by visual analogue scale (VAS) at week 12
Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change from baseline on genital ulcer pain as measured by visual analogue scale (VAS) at week 12
Pain of genital ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change from baseline in disease activity as measured by Behçet's Disease Current Activity Form (BDCAF)
The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, The score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates a higher level of disease activity, and a negative change from baseline indicates improvement. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, and the Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7. A higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change from baseline in disease activity as measured by Behçet's Syndrome Activity Score (BSAS) at Week 12
The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change from baseline in Behçet's Disease Quality of Life (BD Qol) Scores at week 12
The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease- related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement.
Time frame: Baseline to week 12
Change From baseline in Short Form-36 Health Status Questionnaire(SF-36)
Short Form-36 Health Status Questionnaire(SF-36) is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: Baseline to week 12
Corticosteroid-tapering effects.
The dosage of glucocorticoids will be tapered tailored to the disease activity of each participant, and the change of dosage from baseline will be recorded.
Time frame: Baseline to week 12
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital